Immune Checkpoint Inhibitors (ICIs) & Inflammatory Bowel Disease (IBD)

There are limited retrospective data regarding the safety of Immune Checkpoint Inhibitors (ICIs) in patients with inflammatory bowel disease (IBD; ulcerative colitis, Crohn’s disease) because they have been generally excluded from clinical trials testing Immune Checkpoint Inhibitors (ICIs)
Grover et al. 2020 JOP 16: e933–e942

Exacerbation of enterocolitis occurred in a notable percentage of patients with Inflammatory Bowel Disease (IBD) and a majority of patients with microscopic colitis, leading to discontinuation of Immune Checkpoint Inhibitors (ICIs)
Grover et al. 2020 JOP 16: e933–e942

Preexisting Inflammatory Bowel Disease (IBD) increases the risk of severe gastrointestinal adverse events in patients treated with Immune Checkpoint Inhibitors (ICIs)
Abu-Sbeih et al. 2020

see also:
Enterocolitis & Immune Checkpoint Inhibitors (ICIs)